An intravenous application of magnetic nanoparticles for osteomyelitis treatment: An efficient alternative

Basit Öğe Kaydı
dc.contributor.authorAk, G.
dc.contributor.authorBozkaya, Ü.F.
dc.contributor.authorYılmaz, H.
dc.contributor.authorSarı Turgut, Ö.
dc.contributor.authorBilgin, İ.
dc.contributor.authorTomruk, C.
dc.contributor.authorHamarat Şanlıer, Ş.
dc.date.accessioned2020-12-01T11:53:03Z
dc.date.available2020-12-01T11:53:03Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractThe infection of bone and bone marrow is called osteomyelitis. Treatment is difficult since antibiotics can not reach with enough concentration to the infected area. For the first time in this study, we have developed gentamicin-loaded magnetic gelatin nanoparticles (GMGNPs) for nanocarrier-mediated and magnetically targeted osteomyelitis therapy. Gelatin, genipin, and magnetite were used for preparation of that novel carrier system due to their biodegradable and biocompatible properties. Cross-linking degree of gelatin nanoparticles, concentration of magnetite nanoparticles, and adsorbed drug amount were optimized. Furthermore, nanoparticles were characterized and the drug release profile was determined. The osteomyelitis model was constituted in the proximal tibia of rats. The therapeutic potential of GMGNPs on rats was monitored via X-Ray radiography and hematological and histopathological analyses were performed. According to the results, 110.3 ± 8.2 µg gentamicin/mg GMGNPs were used, hydrodynamic size was measured as 253.7 ± 11.8 nm, and GMGNPs have controlled drug release profile. Based on in vivo and ex vivo studies, after six doses of GMGNPs treatment, abscess began to heal and the integrity of periost and bone began to reconstruct. In conclusion, it can be suggested that GMGNPs could provide efficient therapy for osteomyelitis. © 2020 Elsevier B.V.en_US
dc.description.sponsorship2014 ILAM 001en_US
dc.description.sponsorshipThis study was financially supported by Ege University Scientific Research Project Office (Grand number: 2014 ILAM 001). We would like to thank Ege University Center for Drug Research & Development and Pharmacokinetic Applications (ARGEFAR) for the laboratory support, Dr. E. Gülben Yurdagül for her interpretation of X-Ray images, Dursun Demiroz for providing illustrations and technical support, and also Erkan Aydın for checking and correcting the language of our article. Patent applications in the national and international areas have been filed for this invention, which have been supported by Ege University (paperwork issue number 78886088 - 604.01.06).en_US
dc.identifier.doi10.1016/j.ijpharm.2020.119999
dc.identifier.issn0378-5173
dc.identifier.issn0378-5173en_US
dc.identifier.pmid33190790en_US
dc.identifier.scopus2-s2.0-85095840846en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2020.119999
dc.identifier.urihttps://hdl.handle.net/11454/61723
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofInternational Journal of Pharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGelatin nanoparticleen_US
dc.subjectGenipinen_US
dc.subjectGentamicinen_US
dc.subjectMagnetic drug targetingen_US
dc.subjectMagnetiteen_US
dc.subjectOsteomyelitisen_US
dc.titleAn intravenous application of magnetic nanoparticles for osteomyelitis treatment: An efficient alternativeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu